Kilitch Drugs Peer Comparison

NSE: KILITCH | BSE: 524500

₹172.52

₹1.15 (0.67%)

As on 03-Sep-2026 15:31IST

Market cap

₹600 Cr

Revenue (TTM)

₹237 Cr

P/E Ratio

P/B Ratio

2.1

Div. Yield

0 %

Edit

	Kilitch Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	600	21,256	21,609	18,069	17,367
Revenue (₹ Cr)	237	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	29.20	735.15	678.07	666.92	169.62
Net Margin (%)	11.74	26.88	28.10	20.60	6.90
RoE (%)	11.02	19.16	19.73	18.75	20.76
Price to Earnings	19.96	28.91	32.48	28.06	102.39
Price-To-Book	2.13	4.82	5.74	4.47	19.21

Income Statement (₹ Cr)

	Kilitch Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	237.21	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	248.79	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	200.94	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	36.27	941.63	796.58	1,139.61	229.86
Depreciation	3.87	57.58	78.10	281.06	17.24
EBIT	32.40	884.05	718.48	858.55	212.62
Interest	4.91	7.69	0.88	190.64	5.72
Other Income	11.58	165.62	125.96	7.45	26.48
Exceptional Items	0.00	-49.16	0.00	-17.24	-5.13
Profit before Tax	39.07	992.82	843.56	658.12	228.25
Provision for Tax	9.86	257.67	165.49	-8.80	58.63
Profit after Tax	29.20	735.15	678.07	666.92	169.62

	Kilitch Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	279.65	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.85	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	59.28	91.50	28.74	1,392.75	134.50
Current Liabilities	121.60	627.48	385.94	2,077.10	981.81
Total Liabilities	457.75	4,921.88	--	7,246.72	2,414.58

	Kilitch Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	235.55	770.28	1,291.22	5,617.77	42.47
Current Assets	222.20	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	457.75	4,921.88	--	7,246.72	2,414.58
Total Debt*	88.71	2.50	--	2,309.68	0.00
Net Current Assets	100.60	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	0.76	370.49	--	51.57	121.23

	Kilitch Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	23.96	967.57	--	537.99	-15.14
Cash Flow from Investing Activities	-100.44	-561.67	--	-369.46	18.69
Cash from Financing Activities	82.45	-798.31	--	-313.53	-91.97
Net Cash Inflow / Outflow	5.97	-392.41	--	-145.00	-88.42

	Kilitch Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	14.50	23.39	--	--	31.24
ROE (%)	11.02	19.16	19.73	18.75	20.76
ROA (%)	7.58	14.95	18.69	9.26	9.67
EBIT Margin (%)	13.66	34.40	31.41	26.58	8.74
Net Margin (%)	11.74	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Kilitch Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	14.04	10.69	15.01	9.59	31.10
EBIT Growth (%)	9.51	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	9.37	-9.09	19.61	62.68	-7.49
EPS Growth (%)	-29.89	14.40	17.73	67.41	-18.33
Book Value Growth (%)	38.28	-0.34	--	--	13.51

	Kilitch Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	14.06	27.55	32.48	27.29	100.08
Price / Book Value	2.13	4.82	5.74	4.45	19.21
Dividend Yield (%)	0.00	1.61	0.14	0.55	0.52
EV/EBITDA	17.10	19.27	25.99	17.77	73.60
Market Cap (₹ Cr)	445.94	21,592.90	--	--	19,398.64

	Kilitch Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.21	0.00	0.00	0.24	0.00
Short term debt to equity ratio	0.11	0.00	--	0.12	--
Current Ratio	1.83	6.06	6.70	0.74	1.77
Quick Ratio	1.73	5.31	5.59	0.53	0.73
Interest Coverage	8.96	130.11	959.59	4.45	40.90

	Kilitch Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	50.66	7.07	36.10	21.07	8.79
Asset Turnover	0.62	0.52	0.63	0.45	1.39
Receivable days	158.82	26.06	--	--	31.88
Inventory Days	20.79	65.95	--	--	126.03
Payable days	193.60	81.01	--	--	163.79
Cash Conversion Cycle	-13.99	11.00	--	--	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.